|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61K 39/00 | (2006.01) |
| (11) | Number of the document | 2077282 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09004064.3 |
| Date of filing the European patent application | 2004-11-05 | |
| (97) | Date of publication of the European application | 2009-07-08 |
| (45) | Date of publication and mention of the grant of the patent | 2016-12-28 |
| (46) | Date of publication of the claims translation | 2017-03-10 |
| (30) | Number | Date | Country code |
| 517096 P | 2003-11-05 | US |
| (72) |
Umana, Pablo, CH
Brünker, Peter, CH
Ferrara Koller, Claudia, CH
Suter, Tobias, CH
Püntener, Ursula, CH
Mössner, Ekkehard, CH
|
| (73) |
Roche Glycart AG,
Wagistrasse 18, 8952 Schlieren-Zuerich,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antigeną surišančios molekulės su padidintu Fc receptoriaus surišimo giminingumu ir efektoriaus funkcija |
| Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| Payment date | Validity (years) | Amount | |
| 2023-10-19 | 347.00 EUR |